Contact
Please use this form to send email to PR contact of this press release:
Cascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib” for Lead Product Candidate ONT-380
TO:
Please use this form to send email to PR contact of this press release:
Cascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib” for Lead Product Candidate ONT-380
TO: